Newsfeeds - Spark Newswire

1 minute read

AbbVie, RegenXBio Ink $1.75B Retinal Gene Therapy Collaboration

Today, 10:54 PM

AbbVie Inc (NYSE:ABBV) and Regenxbio Inc (NASDAQ:RGNX) have partnered to develop and commercialize RGX-314, potential one-time gene therapy for wet age-related macular degeneration…

ABBV

1 minute read

12 Health Care Stocks Moving In Monday’s Pre-Market Session

By Benzinga Insights

Today, 10:54 PM

ADAP

2 minute read

AbbVie And REGENXBIO Announce Eye Care Collaboration; AbbVie To Pay REGENXBIO $370M Upfront Payment And Up To $1.38B In milestones

By Bill Haddad

Today, 10:54 PM

AbbVie (NYSE:ABBV) and REGENXBIO Inc. (NASDAQ:RGNX) today announced a partnership to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (wet

ABBV

1 minute read

Regenxbio Q2 EPS $(1.36) Misses $(1.12) Estimate, Sales $22.00M Miss $29.02M Estimate

By Benzinga Newsdesk

Today, 10:54 PM

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.12) by 21.43 percent. This is a 49.45 percent decrease over losses of $(0.91) per share from the

RGNX

14 minute read

Earnings Scheduled For August 9, 2021

By Benzinga Insights

Today, 10:54 PM

Companies Reporting Before The Bell • Privia Health Group (NASDAQ:PRVA) is projected to report quarterly loss at $1.57 per share on revenue of $215.17 million.

ACM

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 10:54 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

2 minute read

18 Key Biopharma Catalysts To Keep An Eye On In Q3

By Shanthi Rexaline

Today, 10:54 PM

Biopharma stocks underperformed in the first half of 2021, and several of these stocks could be in for a rebound in the coming months. Needham analyst Serge Belanger highlighted companies in the firm's coverage universe that have key catalysts in the third quarter.

ACER

5 minute read

Uncategorized

The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts

By Shanthi Rexaline

Today, 10:54 PM

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)

ACHL

6 minute read

Uncategorized

The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings

By Shanthi Rexaline

Today, 10:54 PM

Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came under pressure following the U.S.

ABCL

26 minute read

Uncategorized

Earnings Scheduled For May 5, 2021

By Benzinga Insights

Today, 10:54 PM

Companies Reporting Before The Bell • Monmouth Real Estate (NYSE:MNR) is likely to report earnings for its second quarter.

AAWW